Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics

Pharmacogenomics

Volumn 15, Issue 16, 2014, Pages 1947-1962

  Tay Sontheimer, Jessica ^a   Shireman, Laura M ^a   Beyer, Richard P ^a   Senn, Taurence ^a   Witten, Daniela ^a   Pearce, Robin E ^b   Gaedigk, Andrea ^b,c   Gana Fomban, Cletus L ^a   Lutz, Justin D ^a   Isoherranen, Nina ^a   Thummel, Kenneth E ^a   Fiehn, Oliver ^d   Leeder, J Steven ^b,c   Lin, Yvonne S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CHILDREN S MERCY HOSPITAL   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biomarker; clinical; CYP2D6; dextromethorphan; endogenous; fluoxetine; metabolomics; pediatric; phenotype

Indexed keywords

BIOLOGICAL MARKER; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; FLUOXETINE; GLUCURONIDE; CYTOCHROME P450 2D6 INHIBITOR; DEXTRORPHAN;

ADOLESCENT; ARTICLE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY QUADRUPOLE TIME OF FLIGHT MASS SPECTROMETRY; MALE; METABOLOMICS; NORMAL HUMAN; PHENOTYPE; PREPUBERTY; QUADRUPOLE MASS SPECTROMETRY; QUANTITATIVE ANALYSIS; SCORING SYSTEM; TIME OF FLIGHT MASS SPECTROMETRY; URINALYSIS; VALIDITY; ADULT; CHILD; GENETICS; URINE;

ADOLESCENT; ADULT; BIOMARKERS; CHILD; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2D6 INHIBITORS; DEXTROMETHORPHAN; DEXTRORPHAN; FEMALE; FLUOXETINE; HEALTHY VOLUNTEERS; HUMANS; MALE; METABOLOMICS;

EID: 84919788320     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.155     Document Type: Article

References (51)

1. Kimland E, Odlind V. Off-label drug use in pediatric patients. Clin. Pharmacol. Ther. 91(5), 796-801 (2012
2. Kimland E, Nydert P, Odlind V, Bottiger Y, Lindemalm S. Paediatric drug use with focus on off-label prescriptions at Swedish hospitals-A nationwide study. Acta Paediatr. 101(7), 772-778 (2012
3. Sachs AN, Avant D, Lee CS, Rodriguez W, Murphy MD. Pediatric information in drug product labeling. JAMA 307(18), 1914-1915 (2012
4. Rodriguez W, Selen A, Avant D, et al. Improving pediatric dosing through pediatric initiatives: what we have learned. Pediatrics 121(3), 530-539 (2008
5. Johnson TN. The problems in scaling adult drug doses to children. Arch. Dis. Child. 93(3), 207-211 (2008
6. Bouzom F, Walther B. Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling. Fundament. Clin. Pharmacol. 22(6), 579-587 (2008
7. Mahmood I. Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br. J. Clin. Pharmacol. 61(5), 545-557 (2006
8. Abernethy DR, Burckart GJ. Pediatric dose selection. Clin. Pharmacol. Ther. 87(3), 270-271 (2010
9. Laer S, Barrett JS, Meibohm B. The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J. Clin. Pharmacol. 49(8), 889-904 (2009
10. Leeder JS, Kearns GL, Spielberg SP, Van Den Anker J. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J. Clin. Pharmacol. 50(12), 1377-1387 (2010
11. Allegaert K, Rochette A, Veyckemans F. Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance. Paediatr. Anaesth. 21(3), 266-273 (2011
12. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem. 392(6), 1093-1108 (2008
13. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet. 48(11), 689-723 (2009
14. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin. Pharmacokinet. 48(12), 761-804 (2009
15. Abduljalil K, Frank D, Gaedigk A, et al. Assessment of activity levels for CYP2D6 1, CYP2D6 2, and CYP2D6 41 genes by population pharmacokinetics of dextromethorphan. Clin. Pharmacol. Ther. 88(5), 643-651 (2010
16. The Human Cytochrome P450 (CYP) Allele Nomenclature Database. www.cypalleles.ki.se/cyp2d6.htm
17. Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation. Int. Rev. Psychiatry 25(5), 534-553 (2013
18. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther. 91(2), 321-326 (2012
19. Hicks JK, Swen JJ, Gaedigk A. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. Curr. Drug Metabol. 15(2), 218-232 (2014
20. Teh LK, Bertilsson L. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metabol. Pharmacokinet. 27(1), 55-67 (2012
21. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83(2), 234-242 (2008
22. Jones AE, Brown KC, Werner RE, et al. Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur. J. Clin. Pharmacol. 66(5), 475-485 (2010
23. Llerena A, Dorado P, Ramirez R, et al. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans. Pharmacogenomics J. 12(2), 176-183 (2012
24. Wu AH. Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance. Clin. Proteomics 8(1), 12 (2011
25. Sager JE, Lutz JD, Foti RS, Davis C, Kunze KL, Isoherranen N. Fluoxetine and norfluoxetine mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19 and CYP3A4. Clin. Pharmacol. Ther.95(6), 653-62-662 (2014
26. Yu AM, Idle JR, Herraiz T, Kupfer A, Gonzalez FJ. Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13(6), 307-319 (2003
27. Jiang XL, Shen HW, Yu AM. Pinoline may be used as a probe for CYP2D6 activity. Drug Metabol. Dispos. 37(3), 443-446 (2009
28. Hiroi T, Kishimoto W, Chow T, Imaoka S, Igarashi T, Funae Y. Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology 142(9), 3901-3908 (2001
29. Snider NT, Sikora MJ, Sridar C, Feuerstein TJ, Rae JM, Hollenberg PF. The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. J. Pharmacol. Exp. Ther. 327(2), 538-545 (2008
30. Sridar C, Snider NT, Hollenberg PF. Anandamide oxidation by wild-Type and polymorphically expressed CYP2B6 and CYP2D6. Drug Metabol. Dispos. 39(5), 782-788 (2011
31. Cheng J, Zhen Y, Miksys S, et al. Potential role of CYP2D6 in the central nervous system. Xenobiotica 43(11), 973-984 (2013
32. Etiology B, Bircher J, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin. Pharmacol. Ther. 38(6), 618-624 (1985
33. Gaedigk A, Fuhr U, Johnson C, Berard LA, Bradford D, Leeder JS. CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. Pharmacogenomics 11(1), 43-53 (2010
34. Gaedigk A, Jaime LK, Bertino JS Jr., et al. Identification of novel CYP2D7-2D6 Hybrids: non-functional and functional variants. Front. Pharmacol. 1, 121 (2010
35. Gaedigk A, Twist GP, Leeder JS. CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR. Pharmacogenomics 13(1), 91-111 (2012
36. Gaedigk A, Isidoro-Garcia M, Pearce RE, et al. Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populations. Eur. J. Clin. Pharmacol. 66(9), 859-864 (2010
37. Blake MJ, Gaedigk A, Pearce RE, et al. Ontogeny of dextromethorphan O-And N-demethylation in the first year of life. Clin. Pharmacol. Ther. 81(4), 510-516 (2007
38. Smith CA, Want EJ, Omaille G, Abagyan R, Siuzdak G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem. 78(3), 779-787 (2006
39. Tautenhahn R, Bottcher C, Neumann S Highly sensitive feature detection for high resolution LC/MS. BMC Bioinform. 9, 504 (2008
40. gee: Generalized Estimation Equation solver. http://cran.r-project.org/web/packages/gee/index.html
41. Tautenhahn R, Cho K, Uritboonthai W, Zhu Z, Patti GJ, Siuzdak G. An accelerated workflow for untargeted metabolomics using the METLIN database. Nat. Biotechnol. 30(9), 826-828 (2012
42. METLIN Metabolite Database. http://metlin.scripps.edu
43. Wishart DS, Knox C, Guo AC, et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 37, D603-610 (2009
44. The Human Metabolome Database. www.hmdb.ca
45. Lutz U, Bittner N, Lutz RW, Lutz WK. Metabolite profiling in human urine by LC-MS/MS: method optimization and application for glucuronides from dextromethorphan metabolism. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 871(2), 349-356 (2008
46. Wang D, Poi MJ, Sun X, Gaedigk A, Leeder JS, Sadee W. Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum. Mol. Genet. 23(1), 268-278 (2014
47. Yokoi T. Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children. J. Toxicol. Sci. 34(Suppl. 2), SP307-SP312 (2009
48. Stevens JC, Marsh SA, Zaya MJ, et al. Developmental changes in human liver CYP2D6 expression. Drug Metabol. Dispos. 36(8), 1587-1593 (2008
49. Gu H, Pan Z, Xi B, et al. 1H NMR metabolomics study of age profiling in children. NMR Biomed. 22(8), 826-833 (2009
50. Yu AM, Idle JR, Byrd LG, Krausz KW, Kupfer A, Gonzalez FJ Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13(3), 173-181 (2003
51. Manolio TA. Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 363(2), 166-176 (2010